Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease

Clinical trial NCT05143528 · UNKNOWN

Trial details

NCT number: NCT05143528
Sponsor: KeifeRx, LLC
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2022-02-01
Primary completion: 2025-12-31
Enrollment: 1275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.